Skip to Main content Skip to Navigation
Journal articles

Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus

Abstract : The global, randomized, double-blind, phase 3 KEYNOTE-189 study(NCT02578680) showed significantly improved OS and PFS with pembrolizumab(pembro)þpemetrexed (pem)þplatinum compared with placeboþpemþplatinumwith a manageable safety profile in pts with previously untreated metastatic nonsqua-mous NSCLC without targetable EGFR/ALK aberrationsj. We present safety and toler-ability data from Japanese pts enrolled in KEYNOTE-189
Complete list of metadatas

Cited literature [4 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02470585
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, March 24, 2020 - 10:29:32 AM
Last modification on : Saturday, March 28, 2020 - 1:55:33 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2020-08-01

Please log in to resquest access to the document

Identifiers

Citation

Erwan Le Tallec, Alain Lescoat, Alice Ballerie, Berengere Cador, Hervé Lena, et al.. Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2020, 15 (2), pp.E29-E30. ⟨10.1016/j.jtho.2019.09.011⟩. ⟨hal-02470585⟩

Share

Metrics

Record views

96